Advancements in nanomedicines for the detection and treatment of diabetic kidney disease

• Published in: Biomaterials and biosystems Vol. 6; p. 100047
• Main Authors: Tillman, Luke, Tabish, Tanveer A., Kamaly, Nazila, Moss, Primrose, El-briri, Amal, Thiemermann, Christoph, Pranjol, Md Zahidul I., Yaqoob, Muhammad M.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2022; Elsevier
• Subjects: Diabetic kidney disease; Diagnosis; Nanoparticles; Review; Theranostics; Treatment; Nanoparticles; Treatment; Diagnosis; Theranostics; Diabetic kidney disease
• ISSN: 2666-5344; 2666-5344
• DOI: 10.1016/j.bbiosy.2022.100047

•CKD is a global health crisis.•Nanomedicine is a promising tool in theranostics of CKD.•Targeting senescence at pre-diabetic stage could prevent end-stage complications. In the diabetic kidneys, morbidities such as accelerated ageing, hypertension and hyperglycaemia create a pro-inflammatory microenvironment characterised by extensive fibrogenesis. Radiological techniques are not yet optimised generating inconsistent and non-reproducible data. The gold standard procedure to assess renal fibrosis is kidney biopsy, followed by histopathological assessment. However, this method is risky, invasive, subjective and examines less than 0.01% of kidney tissue resulting in diagnostic errors. As such, less than 10% of patients undergo kidney biopsy, limiting the accuracy of the current diabetic kidney disease (DKD) staging method. Standard treatments suppress the renin-angiotensin system to control hypertension and use of pharmaceuticals aimed at controlling diabetes have shown promise but can cause hypoglycaemia, diuresis and malnutrition as a result of low caloric intake. New approaches to both diagnosis and treatment are required. Nanoparticles (NPs) are an attractive candidate for managing DKD due to their ability to act as theranostic tools that can carry drugs and enhance image contrast. NP-based point-of-care systems can provide physiological information previously considered unattainable and provide control over the rate and location of drug release. Here we discuss the use of nanotechnology in renal disease, its application to both the treatment and diagnosis of DKD. Finally, we propose a new method of NP-based DKD classification that overcomes the current systems limitations.